Background Deficiency of the thyroid hormone transporter monocarboxylate transporter 8 (MCT8) causes severe intellectual and motor disability and high serum tri-iodothyronine (T3) concentrations (Allan–Herndon–Dudley syndrome). This chronic thyrotoxicosis leads to progressive deterioration in bodyweight, tachycardia, and muscle wasting, predisposing affected individuals to substantial morbidity and mortality. Treatment that safely alleviates peripheral thyrotoxicosis and reverses cerebral hypothyroidism is not yet available. We aimed to investigate the effects of treatment with the T3 analogue Triac (3,3′,5-tri-iodothyroacetic acid, or tiratricol), in patients with MCT8 deficiency.
MTG8
Thyroid
The first patient meeting for Eastern European countries on thyroid diseases
On May 10th and 11th, The Bulgarian organisation VIOM (a patient organisation for thyroid diseases) organised the first patient meeting for Central/South-Eastern European countries on thyroid diseases, at the same time as the First Scientific Conference for Central and Eastern Europe on the Thyroid Diseases.
Main Thematic Group 8: Thyroid meeting
Members of the Main Thematic Group (MTG) 8: Thyroid met in Paris, at Necker Enfants Malades University Hospital, on the 23rd of January 2019 to discuss the ongoing work and progress of the MTG and it’s subgroups. Chair of MTG8, Michel Polak, wrote a short report about the meeting.